Clinical efficacy of prostatectomy combined with neoadjuvant endocrine therapy.
- Author:
Hai-Jian YUAN
1
;
Kai-Yun CHU
1
;
Wei-Dong XU
1
Author Information
1. Department of Urology, Hai'an People's Hospital, Hai'an, Jiangsu 226600, China.
- Publication Type:English Abstract
- Keywords:
radical prostatectomy;
neoadjuvant endocrine therapy;
prostate cancer;
symptom improvement;
immune function
- MeSH:
Humans;
Male;
Prostatectomy;
Prostatic Neoplasms/drug therapy*;
Neoadjuvant Therapy;
Vascular Endothelial Growth Factor A/blood*;
Middle Aged;
Prostate-Specific Antigen/blood*;
Aged;
Treatment Outcome
- From:
National Journal of Andrology
2025;31(4):323-327
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical effect of prostatectomy combined with neoadjuvant endocrine therapy.
METHODS:A total of 147 prostate cancer patients who were treated at the Hai'an People's Hospital from January 2019 to December 2023 were enrolled in the study. The patients were randomly divided into three groups using a random number table, with 49 cases in each group. The patients in control group 1 were treated with radical prostatectomy alone. Endocrine therapy was performed in control group 2. And the patients in observation group received radical prostatectomy combined with neoadjuvant endocrine therapy. Clinical indicators, improvement of prostate symptoms (measured by the IPSS), immune function (CD3+, CD4+, CD4+/CD8+ ratio), serum levels (PSA and vascular endothelial growth factor ［VEGF］), and complications were compared among the three groups. A one-year postoperative follow-up was conducted to monitor recurrence.
RESULTS:After treatment, the patients in observation group had shorter operative time and lymph node dissection time, less intraoperative blood loss, and lower rate of positive surgical margins compared to control group 1. The IPSS score in the observation group was significantly lower than that in control group 1 and control group 2. The levels of CD3+, CD4+, and the CD4+/CD8+ ratio were higher in the observation group compared to the other two groups. The serum levels of PSA and VEGF were lower in the observation group. The incidence of complications in observation group was lower compared to both control groups. And the recurrence rate after one year was lower in the observation group than that in the other two groups. All differences were statistically significant (P<0.05).
CONCLUSION:The clinical indicators, immune function, levels of PSA and VEGF as well as postoperative complications can be improved through radical prostatectomy combined with neoadjuvant endocrine therapy.
